Of the various medical therapies for heart failure (HF), sacubitril/valsartan is a first-in-class
angiotensin receptor-neprilysin inhibitor that combines sacubitril, a pro-drug that is further …

Background Sacubitril/valsartan is an angiotensin receptor–neprilysin inhibitor indicated for
the treatment of patients with chronic heart failure (HF) with reduced ejection fraction; …

Introduction: Sacubitril-valsartan is a combination drug that contains the neprilysin inhibitor
sacubitril and angiotensin II receptor blocker valsartan. In 2015, the US Food and Drug …

Study Objective Despite evidence that supports the use of sacubitril/valsartan–the first
angiotensin II receptor blocker–neprilysin inhibitor–for mortality reduction in patients with …

Background. Currently, data on sacubitril/valsartan therapy from the real-world settings are
scarce and the predictors of a good clinical responsiveness to this drug are unknown …

Valsartan/sacubitril (Entresto, Novartis) is a combination of the neprilysin inhibitor sacubitril
and the angiotensin receptor antagonist valsartan. In July 2015, the US Food and Drug …

Objective: To evaluate the clinical role of sacubitril/valsartan, a novel angiotensin–neprilysin
inhibitor, for the treatment of chronic heart failure with a reduced ejection fraction (HFrEF) …

Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the
valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with …

Sacubitril/valsartan (S/V) is a pharmaceutical strategy that increases natriuretic peptide
levels by inhibiting neprilysin and regulating the renin-angiotensin-aldosterone pathway …

With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …